Japan's NEC Expands Biopharma Presence With AI-Based R&D
Now in Norway, Netherlands and Germany
Executive Summary
Japanese tech major re-structures its teams for artificial intelligence-based drug development and strategies while expanding its presence in Europe. With confidence in the utility of AI for discovery, it is retaining a key focus on oncology while adding infectious diseases to its targets.
You may also be interested in...
Asia Deal Watch: Juniper Licenses Asia-Pacific-Plus Rights To Kolon’s Osteoarthritis Cell Therapy
Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.
NEC Moves Beyond IT Tools As It Pursues AI-Driven Drug Discovery Initiative
In an exclusive interview, Japanese tech giant NEC tells Scrip it is aiming for much more than the provision of IT tools in its AI-assisted Drug Discovery Initiative, hoping also to progress assets deriving from cutting-edge technology research.
Asia Deal Watch: Busy Eikon Partners With Impact On Selective PARP1 Inhibitors
Yuhan and J INTS BIO and Betta and C4 sign deals centered on lung cancer candidates. Viatris’s Japanese affiliate gets in-country rights to InDex’s Phase III ulcerative colitis candidate.